<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03899987</url>
  </required_header>
  <id_info>
    <org_study_id>I 77318</org_study_id>
    <secondary_id>NCI-2019-01192</secondary_id>
    <secondary_id>I 77318</secondary_id>
    <secondary_id>P30CA016056</secondary_id>
    <nct_id>NCT03899987</nct_id>
  </id_info>
  <brief_title>Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery</brief_title>
  <official_title>Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIM ImmunoTech Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well aspirin and rintatolimod with or without&#xD;
      interferon-alpha 2b work in treating patients with prostate cancer before surgery. Aspirin&#xD;
      may help to keep the prostate cancer from coming back. Rintatolimod may stimulate the immune&#xD;
      system and interfere with the ability of tumor cells to grow and spread. Interferon-alpha 2b&#xD;
      may improve the body's natural response to infections and may slow tumor growth. It is not&#xD;
      yet known how well rintatolimod, aspirin, and interferon-alpha 2b work in treating patients&#xD;
      with prostate cancer undergoing surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the immunomodulatory effectiveness of the combination of rintatolimod and aspirin&#xD;
      with or without recombinant interferon alfa-2b (interferon [IFN]-alpha), in participants with&#xD;
      localized prostate cancer undergoing radical prostatectomy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the safety and toxicity of the treatment combinations in participants with&#xD;
      localized prostate cancer undergoing radical prostatectomy.&#xD;
&#xD;
      II. Assess the antitumor activity between treatment arms.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Compare the resected tumor tissue specimen and surrounding tissue samples of both study&#xD;
      arms (pre versus [vs] post-chemokine modulatory [CKM] treatment, with vs without CKM, CKM&#xD;
      doublet vs CKM triplet) with regards to infiltrating T cell subtypes, effector T cell&#xD;
      (Teff)/regulatory T cell (Treg) ratios, CD11b+ myeloid-derived suppressor cell (MDSC); the&#xD;
      expression of chemokine receptors and immune checkpoint molecules on immune cells; local&#xD;
      expression of Teff-attracting chemokines and Treg/MDSC-favoring chemokines; ribonucleic acid&#xD;
      (RNA) signatures of groups of immune-regulatory genes that are modulated by the CKM regimen.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 3 arms.&#xD;
&#xD;
      ARM I: Patients receive aspirin orally (PO) two times a day (BID) from day -7 to 7 days prior&#xD;
      to surgery. Patients also receive recombinant interferon alfa-2b intravenously (IV) over 20&#xD;
      minutes and rintatolimod IV over 2 hours on days 1-3, and 8-10 in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or&#xD;
      between day 17-24.&#xD;
&#xD;
      ARM II: Patients receive aspirin PO BID from day -7 to 7 days prior to surgery and&#xD;
      rintatolimod IV over 2 hours on days 1-3 and 8-10 in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24.&#xD;
&#xD;
      ARM III: Patients undergo radical prostatectomy about 4 weeks after enrollment.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Anticipated">January 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of tumor infiltrating CD8+ lymphocytes</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>This will be assessed by the increase in the total number of tumor infiltrating CD8+ T cells in the radical prostatectomy specimen (measured as cell density of CD8+ cell by immunohistochemistry), comparing Arm A versus Arm B versus Arm C. Will be natural log transformed prior to analysis. The primary analysis will consist of testing the single degree of freedom planned contrast at alpha = .10 that the 3 treatment means are in the ratio of 3:2:1 (contrast coefficients 3, -2, -1) for groups A, B and C, respectively groups. If this test rejects the null hypothesis of no group differences, will proceed to estimate group means and pairwise differences between groups with 90% confidence intervals. Non-overlapping confidence intervals will serve as evidence of differential treatment effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Spearman rank correlation coefficients will be used to estimate the correlation between CD8+ tumor infiltrate, pathologic response rate and prostate specific antigen (PSA) response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Surgical margin positivity</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Spearman rank correlation coefficients will be used to estimate the correlation between CD8+ tumor infiltrate, pathologic response rate and PSA response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related adverse events</measure>
    <time_frame>Up to 30 days post treatment</time_frame>
    <description>Will be evaluated with National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Stage I Prostate Cancer AJCC v8</condition>
  <condition>Stage II Prostate Cancer AJCC v8</condition>
  <condition>Stage IIA Prostate Cancer AJCC v8</condition>
  <condition>Stage IIB Prostate Cancer AJCC v8</condition>
  <condition>Stage IIC Prostate Cancer AJCC v8</condition>
  <condition>Stage III Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIA Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIB Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIC Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Arm I (aspirin, interferon alpha, rintatolimod, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive aspirin PO BID on days -7 to 7. Patients also receive recombinant interferon alfa-2b IV over 20 minutes and rintatolimod IV over 2 hours on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (aspirin, rintatolimod, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive aspirin PO BID on days -7 to 7 and rintatolimod IV over 2 hours on days 1-3,and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (radical prostatectomy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo radical prostatectomy about 4 weeks after enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (aspirin, interferon alpha, rintatolimod, surgery)</arm_group_label>
    <arm_group_label>Arm II (aspirin, rintatolimod, surgery)</arm_group_label>
    <other_name>Acetylsalicylic Acid</other_name>
    <other_name>ASA</other_name>
    <other_name>Aspergum</other_name>
    <other_name>Ecotrin</other_name>
    <other_name>Empirin</other_name>
    <other_name>Entericin</other_name>
    <other_name>Extren</other_name>
    <other_name>Measurin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Prostatectomy</intervention_name>
    <description>Undergo radical prostatectomy</description>
    <arm_group_label>Arm I (aspirin, interferon alpha, rintatolimod, surgery)</arm_group_label>
    <arm_group_label>Arm II (aspirin, rintatolimod, surgery)</arm_group_label>
    <arm_group_label>Arm III (radical prostatectomy)</arm_group_label>
    <other_name>Prostatovesiculectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Interferon Alfa-2b</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (aspirin, interferon alpha, rintatolimod, surgery)</arm_group_label>
    <other_name>Alfatronol</other_name>
    <other_name>Glucoferon</other_name>
    <other_name>Heberon Alfa</other_name>
    <other_name>IFN alpha-2B</other_name>
    <other_name>Interferon alfa 2b</other_name>
    <other_name>Interferon Alfa-2B</other_name>
    <other_name>Interferon Alpha-2b</other_name>
    <other_name>Intron A</other_name>
    <other_name>Sch 30500</other_name>
    <other_name>Urifron</other_name>
    <other_name>Viraferon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rintatolimod</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (aspirin, interferon alpha, rintatolimod, surgery)</arm_group_label>
    <arm_group_label>Arm II (aspirin, rintatolimod, surgery)</arm_group_label>
    <other_name>Ampligen</other_name>
    <other_name>Atvogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed, localized prostate adenocarcinoma patients who are planning&#xD;
             to have a radical prostatectomy.&#xD;
&#xD;
          -  Diagnostic prostate biopsy must have been obtained within 6 months patients who had&#xD;
             biopsies at outside facilities may be eligible if tissue availability and adequacy can&#xD;
             be confirmed by pathology.&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Platelet &gt;= 75,000/uL.&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL.&#xD;
&#xD;
          -  Hematocrit &gt;= 27%.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/uL.&#xD;
&#xD;
          -  Creatinine &lt; institutional upper limit of normal (ULN) OR creatinine clearance &gt;= 50&#xD;
             mL/min for patients with creatinine levels greater than ULN.&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 X institutional ULN.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 1.5 X&#xD;
             institutional ULN.&#xD;
&#xD;
          -  Serum amylase and lipase =&lt; 1.5 X institutional ULN.&#xD;
&#xD;
          -  Negative hepatitis panel for patients with a history of Hepatitis&#xD;
&#xD;
          -  Participant must understand the investigational nature of this study and sign an&#xD;
             Independent Ethics Committee/Institutional Review Board approved written informed&#xD;
             consent form prior to receiving any study related procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients currently treated with systemic immunosuppressive agents, including steroids,&#xD;
             are ineligible until 3 weeks after removal from immunosuppressive treatment.&#xD;
&#xD;
          -  Patients who received hormonal therapy, 5-alpha reductase inhibitors (such as&#xD;
             finasteride, dutasteride), chemotherapy, radiotherapy, major surgery, or biologic&#xD;
             therapy within 3 weeks of protocol treatment.&#xD;
&#xD;
          -  Patients with active prostatitis.&#xD;
&#xD;
          -  Patients with active autoimmune disease or history of transplantation.&#xD;
&#xD;
          -  Patients with comorbid medical conditions that render them unfit for surgery.&#xD;
&#xD;
          -  Metastatic disease based on preoperative imaging.&#xD;
&#xD;
          -  Cardiac risk factors including:&#xD;
&#xD;
               -  Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial&#xD;
                  infarction, or ischemia) within 3 months of signing consent&#xD;
&#xD;
               -  Patients with a New York Heart Association classification of III or IV.&#xD;
&#xD;
          -  History of upper and lower gastrointestinal ulceration, upper gastrointestinal&#xD;
             bleeding, or perforation within the past 3 years.&#xD;
&#xD;
          -  History of bleeding disorders, known lesions at risk for bleeding, or history of&#xD;
             recent clinically significant bleed or hemorrhage (&lt;3months).&#xD;
&#xD;
          -  Prior allergic reaction or hypersensitivity to aspirin, or other nonsteroidal&#xD;
             antiinflammatory drugs (NSAIDs).&#xD;
&#xD;
          -  Patients are ineligible if they plan on use of other NSAIDs at any dose during the&#xD;
             trial. Patients who agree to stop regular NSAIDs are eligible and no wash out period&#xD;
             is required.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements.&#xD;
&#xD;
          -  Any condition which in the investigator?s opinion deems the participant an unsuitable&#xD;
             candidate to receive study drug.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gurkamal S Chatta</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gurkamal S. Chatta</last_name>
      <phone>716-845-3863</phone>
      <email>Gurkamal.Chatta@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Gurkamal S. Chatta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>poly(I).poly(c12,U)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

